# R1 CLINICAL-SAFETY REVIEW - hereditary_papillary_renal_carcinoma

VERDICT: APPROVE

Disease id: hereditary_papillary_renal_carcinoma
Source cited: DeVita, Hellman & Rosenberg, Cancer: Principles & Practice of Oncology, 12th ed.; NCCN (general standard where labelled)
Adversarial verdict reviewed: hereditary_papillary_renal_carcinoma.verdict.md = CLEAN (prior blocking finding fixed, no residual flagged issue)

## 1. SAFETY - PASS
No unsafe, misleading, or absolute directives. The narrative is decision-support in tone throughout:
nephron-sparing surgery is "preferred whenever technically feasible," surveillance-and-treat uses a
size/growth threshold rather than treating every lesion, and systemic therapy is "reserved for"
advanced disease. Foretinib is explicitly framed as "supportive evidence for MET-directed therapy...
not as an established or preferred regimen." The 30% remnant-kidney / dialysis-avoidance and >90% T1
cancer-specific-survival statements are descriptive prognostic context, not action thresholds a
clinician could misapply to harm. No false-negative risk (no claim that any modality is safe to omit).
Adjuvant systemic therapy is correctly stated as NOT supported for HPRC/papillary histology, avoiding
overtreatment.

## 2. GROUNDING - PASS
Treatment claims are consistent with DeVita/NCCN standard of care. The adversarial pass spot-checked
each specific claim against devita.txt (foretinib phase II in bilateral/multifocal/metastatic papillary
RCC and germline-MET HPRC; multifocal/familial RCC as partial-nephrectomy indication; 30% remnant
threshold; pre-surgical TKI downstaging; thermal ablation <3 cm; lymphadenectomy limited benefit; SBRT
palliative-only for IVC involvement; everolimus cross-histology/third-line positioning; ASSURE/SORCE/
ATLAS/PROTECT/ARISER adjuvant roster; adjuvant pembrolizumab RFS in clear-cell). Foretinib is genuinely
in DeVita's HPRC section, so it is not mis-attributed. Every claim not in DeVita's disease-specific text
is explicitly labelled "(general oncology standard, not from DeVita's section on this disease)". No
fabricated or outdated regimen. No claim mis-attributed to DeVita.

## 3. DOSE-FREE - PASS
No numeric drug dose, mg, mg/m2, AUC, or numbered schedule. All numerals are non-dose descriptive stats
(<35 kindreds, penetrance by age 80, chromosome 7 trisomy, >90% T1 CSS, 30% remnant, <3 cm ablation
cutoff, 12th ed.). Foretinib named without dose/schedule, as required.

## 4. SCOPE - PASS
Appropriately hedged. Defers systemic-agent selection to current NCCN guidance and clinical-trial
enrollment given disease rarity; explicitly declines to name a preferred regimen or sequencing beyond
the one DeVita-reported data point; states adjuvant treatment "should not be presented as standard."
Referral guidance (urologic oncology, clinical genetics, medical oncology at unresectable/metastatic
stage) is standard and non-directive.

## 5. ADVERSARIAL FLAGS - CLEARED
The .verdict.md returned CLEAN. The single prior blocking finding (the earlier draft's false claim that
DeVita does not name/validate any HPRC-specific agent) has been corrected consistently across all five
locations; no flagged ungrounded/mis-sourced/scope-creep claim remains present. Nothing forces a REVISE.

## Advisory (non-blocking)
- Narrative is long and section-heavy for a management field; trimming would aid clinician readability,
  but content correctness is not affected.
- "typically presenting in the sixth and seventh decades" is descriptive epidemiology; acceptable, though
  onset in HPRC is variable - not a safety issue.

goldens changed: no (intended: n) - this is a KB reference-content draft; no clinical engine, calculator,
interaction table, or golden fixture is touched.
